CTOs on the Move

Walgreens Boots Alliance

www.walgreensbootsalliance.com

 
Walgreens Boots Alliance (Nasdaq: WBA) is the first global pharmacy-led, health and wellbeing enterprise. The company`s heritage of trusted health care services through community pharmacy care and pharmaceutical wholesaling dates back more than 100 years. Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across the U.S. and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 25* countries and employ more than 385,000* people. The company is a global leader in pharmacy-led, health and wellbeing retail and, together with the companies in which ...
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Vish Sankaran
Global Chief Innovation Officer Profile
Alejandro Martinez-Galindo
Senior Vice President of Global Information Technology Transformation and Digital and Information Technology Shared Services Profile
John Rivera
Director Information Security Engineering Profile
Nathan Chandler
Global Director, Cyber Threat Detection and Response Profile
Mike Maresca
Global Chief Technology Officer Profile

Similar Companies

PCI Synthesis

PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products.

Phlow

Securing our nation’s pharmaceuticals through U.S. Manufacturing.

Attenua

Attenua, Inc. is a pharmaceutical company developing antitussive medications.

Vidantus Alliance

Vidantus Alliance is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.